Next Article in Journal
Nanostructured Strategies for Melanoma Treatment—Part II: Targeted Topical Delivery of Curcumin via Poloxamer-Based Thermosensitive Hydrogels
Previous Article in Journal
Immunomodulatory Effects of a Standardized Botanical Mixture Comprising Angelica gigas Roots and Pueraria lobata Flowers Through the TLR2/6 Pathway in RAW 264.7 Macrophages and Cyclophosphamide-Induced Immunosuppression Mice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 18
Issue 3
10.3390/ph18030338
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Retraction of Pharmaceuticals 2021, 14(3), 254.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Retraction

RETRACTED: El-Gowily et al. Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells. Pharmaceuticals 2021, 14, 254

by
Afnan H. El-Gowily
1,*,
Samah A. Loutfy
2,3,
Ehab M. M. Ali
4,5,
Tarek M. Mohamed
1,* and
Mohammed A. Mansour
1,6,*
1
Biochemistry Division, Department of Chemistry, Faculty of Science, Tanta University, Tanta 31527, Egypt
2
Virology & Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt
3
Nanotechnology Research Center, British University, Cairo, Egypt
4
Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia
5
Chemistry Department, Faculty of Science, Tanta University, Tanta 31527, Egypt
6
Division of Human Sciences, School of Applied Sciences, London South Bank University, London SE1 0AA, UK
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(3), 338; https://doi.org/10.3390/ph18030338
Submission received: 6 January 2025 / Accepted: 17 February 2025 / Published: 27 February 2025
(This article belongs to the Section Pharmacology)
Versions Notes
The journal retracts the article titled “Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells.” [1], cited above.
Following the article’s publication, concerns were brought to the attention of the Editorial Office regarding the reliability of the figures presented in this article [1].
Adhering to our complaints procedure, the investigation was conducted by the Editorial Office and Editorial Board. During this process, the authors were unable to satisfactorily explain the similarities between Figure 4(I-A) and Supplementary Figure S5(C II), nor could they provide the raw materials for the Editorial Board evaluation. As a result, the Editorial Board has lost confidence in the reliability of the findings and decided to retract this publication [1], as per MDPI’s retraction policy (https://www.mdpi.com/ethics#_bookmark30, accessed on 6 January 2025).
This retraction was approved by the Editor-in-Chief of Pharmaceuticals.
The authors disagree with this decision.

Reference

  1. El-Gowily, A.H.; Loutfy, S.A.; Ali, E.M.M.; Mohamed, T.M.; Mansour, M.A. RETRACTED: Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells. Pharmaceuticals 2021, 14, 254. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

El-Gowily, A.H.; Loutfy, S.A.; Ali, E.M.M.; Mohamed, T.M.; Mansour, M.A. RETRACTED: El-Gowily et al. Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells. Pharmaceuticals 2021, 14, 254. Pharmaceuticals 2025, 18, 338. https://doi.org/10.3390/ph18030338

AMA Style

El-Gowily AH, Loutfy SA, Ali EMM, Mohamed TM, Mansour MA. RETRACTED: El-Gowily et al. Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells. Pharmaceuticals 2021, 14, 254. Pharmaceuticals. 2025; 18(3):338. https://doi.org/10.3390/ph18030338

Chicago/Turabian Style

El-Gowily, Afnan H., Samah A. Loutfy, Ehab M. M. Ali, Tarek M. Mohamed, and Mohammed A. Mansour. 2025. "RETRACTED: El-Gowily et al. Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells. Pharmaceuticals 2021, 14, 254" Pharmaceuticals 18, no. 3: 338. https://doi.org/10.3390/ph18030338

APA Style

El-Gowily, A. H., Loutfy, S. A., Ali, E. M. M., Mohamed, T. M., & Mansour, M. A. (2025). RETRACTED: El-Gowily et al. Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells. Pharmaceuticals 2021, 14, 254. Pharmaceuticals, 18(3), 338. https://doi.org/10.3390/ph18030338

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop